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ACE inhibitors are associated with a variety of signs and symptoms. The following, but 
not limited too, are some of them. The most common symptom is a cough. The patients 
should notify the health care provider immediately because they may be experiencing a 
potential reaction to the medication. According to Wadelius et al., (2014), the following 
are possible risk factors and side effects (p. 479).
Angiotensin-converting enzyme 
inhibitor (ACEI) medications are one of 
the leading causes of angioedema in the 
United States, also known as ACEI-RA 
(Chan & Soliman, 2015, p. 207). ACE 
inhibitors are among the most 
commonly prescribed medications 
worldwide because they are indicated 
for the management of hypertension, 
congestive heart failure, myocardial 
infarction, diabetic nephropathy, and 
chronic kidney disease (Chan & Soliman, 
2015, p. 207). According to Spencer 
(2016), there are an estimated 40 
million people taking ACE inhibitors for 
either hypertension or congestive heart 
failure (CHF). Angioedema is estimated 
to occur in 0.1%-0.7% of patients on 
ACE inhibitor therapy. Of those who 
present to the emergency department 
with angioedema, 35% of cases are 
attributed to ACEI. Additionally, one 
study concluded that African-Americans 
are three times more likely to develop 
ACEI-RA within six months of starting 
ACE inhibitor therapy (Spencer, 2016). 
0.7% may seem like a small number, but 
that is about twenty-eight thousand 
patients a year. There are several risk 
factors for developing ACE inhibitor 
angioedema. The primary risk factor is 
being African-American. The female 
population, with a history of 
angioedema and chronic disease are all 
contributing factors. What may seem 
odd is that it does not matter how long 
a patient is taking the medication 
before they develop a reaction. Some 
patients have taken the medication for 
more than 20 years before they had a 
reaction. Understanding Angio-
converting enzyme inhibitors are 
important for all parties involved. As a 
healthcare provider who is going to be 
writing prescriptions, it is paramount to 
know the patients’ health background 
and how ACEI works on a cellular level. 
Only after obtaining all the correct 
information will the healthcare provider 
choose whether this medication is right 
for the patient. Do the risks outweigh 
the benefits or vice versa?
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(Wadelius et al., 2014, p. 479)
Implications for 
Nursing Care
ACEIs are very effective in treating 
chronic diseases. APPs must be vigilant 
in screening their patients as well as 
their family members (if possible) 
before prescribing these medications. 
Nurses and APPs will need to provide 
educational material patients. The 
health and wellness of each patient is 
essential. This author wants to educate 
the community on the signs and 
symptoms of ACEI-RA as well as the 
pathophysiology.
Conclusion
antihistamines, and corticosteroids. 
Because ACEI angioedema is not mediated 
by mast cell degranulation, the efficacy of 
these medications remains controversial 
(Winter, Rosenbaum, Vilke, & Almazroua, 
2013, p. 777). According to Scalese & 
Reinaker (2016), a medication called 
icatibant (Firazyr), which is administered 
only once subcutaneously at a dose of 
30mg, has proven to be extremely 
successful in treating ACEI-RA. . How this 
medication works is by blocking the 
bradykinin at the B2 receptor site. By 
doing this the vasodilation effects of 
bradykinin are rendered ineffective, thus 
decreasing the swelling. Icatibant works 
within minutes of administration and can 
prevent invasive procedures that 
otherwise, may be needed to ensure an 
effective airway (Scalese & Reinaker, 2016, 
p. 876) The downside to this medication is 
that it costs $10,000 to $12,000 per dose. 
This author believes that there is no 
amount of money you can put on 
someone’s life. A night in the intensive 
care unit will cost much more. Fresh frozen 
plasma, C1 inhibitor, and icatibant appear 
to be safe and effective options for 
treating ACE
Angioedema is a potentially life-
threatening adverse effect of ACE 
inhibitors, with a reported incidence of 0.1 
to 6%. ACE-inhibitor–related angioedema is 
asymmetric, nonpitting, nontender edema 
that can appear anywhere on the body but 
commonly affects the head and neck area 
(Chan & Soliman, 2015 (p. 207).  According 
to Chan and Soliman (2015), ACEI-RA is not 
considered a true allergic reaction but is 
considered an adverse class effect 
secondary to the mechanism of action (p. 
207). A true allergic reaction would involve 
IgE antibodies. Interestingly, ACEI-RA is not 
IgE mediated; the physiology of the 
condition is caused by the levels of the 
blood vessel-dilating peptide bradykinin in 
the body (Spencer, 2016). Bradykinin 
counterbalances the vasoconstrictive 
workings of the renin-angiotensin-
aldosterone system and is thought to be a 
primary mediator in nonallergic 
angioedemas (Spencer, 2016). ACE 
inhibitors, medications with a –pril suffix  
(e.g., captopril, lisinopril [Prinivil®], 
fosinopril [Monopril®]), lower blood pressure 
by inhibiting the action of angiotensin-
converting enzyme, thus interrupting the 
conversion of angiotensin I to angiotensin II (a 
potent vasodilator) and aldosterone (Wilson 
et al., 2014; Wynn & Maxey, 2012). ACE 
inhibitors also prevent the breakdown of the 
enzyme bradykinin (Felicilda-Reynaldo & 
Kenneally, 2015, p. 180). Bradykinin in low 
doses causes vasodilation, which potentiates 
the action of ACE inhibitors to lower blood 
pressure (Felicilda-Reynaldo & Kenneally, 
2015, p. 180).
Underlying 
Pathophysiology
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Significance of 
Pathophysiology
Understanding how the 
pathophysiology of Angiotensin-
converting enzyme inhibitor (ACEI) is 
essential in deciding if this medication is 
correct to resolve the patient’s 
hypertension. This medication can lead to 
severe swelling, possible intubation or 
even tracheostomy placement. Patients 
with allergic emergencies presenting to 
an ED often receive medications including 
epinephrine, 
inhibitor–induced angioedema, whereas 
antihistamines and corticosteroids do 
not target the underlying mechanism 
(Scalese & Reinaker, 2016, p. 874). 
ACE inhibitor angioedema is a 
relatively common side effect. These 
side effects could be seen in all clinical 
care settings. As the bedside nurse, it 
is important to be able to recognize 
the signs and symptoms of ACEI-Ra 
quickly. As an Advanced Practicing 
Provider, it will be imperative to know 
these patients will not present like a 
typical allergic reaction i.e. itching, 
urticaria. These patients will not be 
treated in the same allergic reaction 
manner. Emergency room nurses need 
to recognize these patients as 
immediate life threats and should be 
seen immediately.  
Patients being seen outside of the 
Emergency room will need to be taken 
to the Emergency room by EMS. 
Advanced practice nurses will need to 
be aware of the risk factors involved in 
prescribing an ACEI to their patients. If 
the risk factors are too high, the 
provider will need to consider an 
alternate medication. The early 
warning sign of a reaction is a chronic 
cough. All patient will need to be 
educated extensively about the signs 
and symptoms of angioedema. 
Written literature will be very helpful 
for the patient to take home.
